The company conducts both animal studies and clinical trials in partnership with renowned university-hospitals in Korea. A wearable prophylactic and acute treatment device for chronic migraine is manufactured in a MDSAP approved manufacturing facility in Korea. The company seeks distributors for the EU region.
The device has two protocols of treatment: preventive and acute protocols, like the typical method of treatment for chronic migraine. By wearing the device for 30 minutes, the device transcutaneous delivers electric current on trigeminal nerve fibers and modulates the autonomic nervous system. All typical types of migraine patients can use the device. It shortens migraine duration, reduces the number of migraine attack, and weakens attack intensity.
It is a medical device in Korea, the US, Europe, and Canada. As approved in the EU region, distribution and sales are needed.